Prospective analysis of the utility of 18-FDG PET in Merkel cell carcinoma of the skin: A Trans Tasman Radiation Oncology Group Study, TROG 09:03.

摘要: INTRODUCTION TROG 09.03 prospectively studied the utility of Fluorine-18 Fluorodeoxyglucose (18-FDG) PET in management Merkel cell carcinoma skin. METHODS Following consent and registration, a pre-treatment FDG-PET/CT was performed. Sites avid disease were confirmed by cytology where practicable. surgery, patients with AJCCv7 Stages IIA-IIIB treated chemo-radiotherapy reassessed post-treatment PET. RESULTS Fifty-eight subjects (45 males 13 females, median age 68 years) enrolled between 2011 2015, 43 whom went on to receive chemo-radiotherapy. An occult primary present 22 (37.9%), T1 (37.9%) T2 14 (24.1%). Nodal 69% cases. Fifty per cent had gross residual at site and/or nodal time registration. 18-FDG PET/CT sensitivity 94.74% (95% CI 82-99.3%) specificity 88.24% 63.56-98.54). The positive predictive value (83.01-98.51) negative 65.81-96.69). influenced treatment decision 27.6% Upstaging occurred 15 (25.9%), no down staging. Other diseases identified 4 (6.9%) patients. Univariate analysis failed demonstrate that SUV levels or any impact overall survival. staged 89% 3-year in-field loco-regional control 76% CONCLUSION Staging 18-FDG-PET significantly decisions approximately one-third cases MCC should be considered routine work-up. Post-treatment not found prognostic. Funding through Medicare Benefits Schedule needs for high risk MCC.